Clinical Trials Logo

Neuropathy clinical trials

View clinical trials related to Neuropathy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05700864 Withdrawn - Neuropathy Clinical Trials

NGF Treatment for Patients With Neuropathic Corneal Pain

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

NCT ID: NCT03436680 Withdrawn - Neuropathy Clinical Trials

Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This trial studies how well a home-based neurofeedback program works in treating participants with chemotherapy-induced peripheral neuropathy (nerve damage that affects motor function). Neurofeedback training is a type of therapy that uses an electroencephalograph and a computer software program to measure brain wave activity. It may help teach participants how to change their own brain waves to lower their perception of pain symptoms and improve overall quality of life.

NCT ID: NCT01492920 Withdrawn - Pain Clinical Trials

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Start date: April 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer undergoing chemotherapy. Acetyl-L-carnitine hydrochloride may prevent or lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine hydrochloride is more effective compared to a placebo in preventing peripheral neuropathy caused by chemotherapy.

NCT ID: NCT00528593 Withdrawn - HIV Infections Clinical Trials

Epoetin Alfa for HIV-Associated Neuropathy Trial

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of epoetin alfa on HIV-associated neuropathy by measuring changes in nerve fiber density and pain ratings.